



Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQB: LVCLY

ASX ANNOUNCEMENT

New milestone as LCT and OptiCellAI advance AI for NTCELL's manufacture

Highlights

- **LCT and OptiCellAI complete first stage of advancing the use of artificial intelligence (AI) in the planned manufacturing of NTCELL in Sydney, Australia**
- **New milestone achieved following receipt of choroid plexus tissue at UTS, as LCT advances third clinical trial of NTCELL in Parkinson's disease.**

Sydney, Australia & Auckland, New Zealand - 16 September 2022 – Living Cell Technologies (ASX:LCT; OTCQB:LVCLY) has achieved a new milestone in its use of artificial intelligence (AI), with OptiCellAI Pty Ltd completing stage one of the planned use of AI in NTCELL's manufacture.

Under the agreement with Sydney-based OptiCellAI (refer ASX announcement 23 May 2022), the two companies are working to ensure that the NTCELL being manufactured in Sydney for the Company's third clinical trial of NTCELL in Parkinson's disease is of the highest possible quality.

AI is being used to optimise and select high quality encapsulated cells (NTCELL) for implantation into the brains of people with Parkinson's disease, as a potential treatment for the disease that affects millions of people globally.

Under the agreement with OptiCellAI, the first stage comprises the finalisation of the necessary hardware, software and testing specifications, together with creating the final design.

This stage has been completed, with OptiCellAI now progressing to the second stage of assembling the necessary software and providing a prototype to LCT for trials (see design below).


Ultimately, the research is expected to result in the development of two prototype machines, together with trained AI for NTCELL optimisation and selection requirements and a final production machine.

LCT's Executive Chairman, Professor Bernie Tuch commented: "We welcome the successful completion of stage one of the AI research with OptiCellAI. This is groundbreaking research with enormous potential, not only for LCT but for Parkinson's disease and medical research globally.

"We look forward to progressing this further with OptiCellAI, as we move towards human trials in Sydney of NTCELL in Parkinson's disease."

In August, LCT received the first shipment of choroid plexus tissue sent from New Zealand to Sydney as part of its third clinical trial. Once production of NTCELL has been optimised at the University of Technology Sydney, it will be manufactured at a Good Manufacturing Practice (GMP) facility.

More than 10 million people worldwide are living with Parkinson's disease, including around 100,000 Australians, with the disease costing the Australian community an estimated \$10 billion per year. Globally, the Parkinson's disease market is projected to reach US\$11.5 billion by 2029, up from US\$5.7 billion in 2022. Currently, no treatment exists to prevent progression of Parkinson's disease.



CC160 Prototype Machine developed by OptiCellAI

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

At the Company: Bernie Tuch Chief Executive Mobile: +61 411 461 604 bernietuch@lctglobal.com	For media queries: Anthony Fensom Republic PR Mobile: +61 407 112 623 anthony@republicpr.com.au
---	---

About NTCELL

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

About Living Cell Technologies

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The Company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information, visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.

References to previous ASX releases

- 16 August – Choroid plexus tissue shipped to Sydney
- 29 July – Quarterly Activities Report
- 23 May – Artificial intelligence to advance NTCELL production
- 30 March – LCT signs Research Agreement with UTS

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.